BioGlyco supplement products (including BioGlyco Flow, BioGlyco Capsules, and BioGlyco Blood) are not affiliated with CD BioGlyco.
CD BioGlyco does not manufacture, distribute, or provide after-sales support for these consumer products. For any product-related questions, please contact the original seller directly.
This highly advanced multi-functional targeted formulation features APGA targeting molecule-modified and artemether loaded liposomes. The structural framework incorporates the hydrophobic sesquiterpene lactone compound artemether directly within the lipophilic hydrocarbon tail domains of its bilayer shell, whose exterior boundary is surface-modified with specific aminopterin-derived aminopterin-pteroylglutamic acid (APGA) targeting ligands linked via covalent polymer-lipid anchors. This complex configuration coordinates a dense target-mimetic ligand array with an optimized sesquiterpene matrix, altering overall surface hydration parameters to completely prevent physical vesicle aggregation while shielding the volatile peroxide bridges of artemether from rapid chemical degradation in open laboratory media.
Thank you for choosing our products for your research. By sharing your publications or experimental feedback, you provide invaluable insights that help fellow scientists accelerate their discoveries. Your contribution also drives our commitment to continuous product optimization.
As a token of our appreciation, verified submissions will receive an exclusive discount code for your next order.
*Submitted research data and images may be featured on our product pages. We strictly protect your personal privacy; no sensitive contact information will ever be disclosed.
CD BioGlyco is a leading biotechnology company specializing in glycobiology. We deliver high-quality products and services to support cutting-edge research worldwide.